

## Accepted Manuscript

*In silico* selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell

Elisa C. Santa Cruz, Adriel R. Carecho, Marta E. Saidel, Carlos Alberto Montanari, Andrei Leitão

PII: S0960-894X(16)31289-6  
DOI: <http://dx.doi.org/10.1016/j.bmcl.2016.12.022>  
Reference: BMCL 24511

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 3 October 2016  
Revised Date: 5 December 2016  
Accepted Date: 7 December 2016



Please cite this article as: Santa Cruz, E.C., Carecho, A.R., Saidel, M.E., Alberto Montanari, C., Leitão, A., *In silico* selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell, *Bioorganic & Medicinal Chemistry Letters* (2016), doi: <http://dx.doi.org/10.1016/j.bmcl.2016.12.022>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

*In silico* selection and cell-based characterization of selective and bioactive compounds for androgen-dependent prostate cancer cell

Elisa C. Santa Cruz, Adriel R. Carecho, Marta E. Saidel, Carlos Alberto Montanari, Andrei Leitão

\*Corresponding author: Andrei Leitão


andleitao@iqsc.usp.br

Av. Trabalhador São-carlense, 400 – São Carlos-SP, Brazil 13566-590

Medicinal Chemistry Group (NEQUIMED)

São Carlos Institute of Chemistry (IQSC) - University of São Paulo (USP)

Graphical abstract



**Abstract**

Prostate cancer is one of the most prevalent types of cancer in male population. It is a hormone driven disease, especially in its initial phase. Hence, androgen deprivation therapy (ADT) is the major chemotherapeutic effort and novel AR inhibitors with improved pharmacological profiles are needed. In this report, a novel bioactive compound was selected and investigated using *in silico* and cell-based assays. Neq0502 compound was selective for the testosterone stimulated AR-dependent prostate cancer cell (LNCaP,  $GI_{50} = 22.4 \mu M$ ) when compared with unstimulated LNCaP or AR-insensitive (DU145 and PC-3) cell lines. Cell cycle arrest study provided the same profile for Neq0502 and the reference drug enzalutamide. Moreover, this compound is not cytotoxic for fibroblast Balb/C 3T3 clone A31 cells up to 250

Download English Version:

<https://daneshyari.com/en/article/5155766>

Download Persian Version:

<https://daneshyari.com/article/5155766>

[Daneshyari.com](https://daneshyari.com)